Introduction
============

The human *BRCA1*gene is under the transcriptional control of two different promoters, α and β that drive the transcription of exon 1a and 1b, respectively \[[@B22]\]. At the RNA level each of the alternative first exons is linked by splicing with exon 2 \[[@B21]\]. However, the translational initiation site is the same for the two mRNA variants and is located in exon 2 \[[@B11]\]. The *BRCA1*5\'UTR region coded by exon 1b contains three additional ATG codons upstream of the major translation initiation site \[[@B21]\]. The promoter α is bidirectional and shared with the NBR2 gene \[[@B4],[@B21]\]. *BRCA1*contains multiple transcription factor binding sites identified in 5\' flanking regions of exon 1a and exon 1b \[[@B17],[@B18]\]. The different transcripts of the *BRCA1*gene are present at different levels in various normal and tumour tissues and may have distinct biological functions \[[@B21]\]. Expression of transcripts α and β of the *BRCA1*gene may be co-regulated by use of a dual promoter system. Moreover, the two mRNAs may differ in their stability or translational efficiency \[[@B21]\].

Germline mutations within the *BRCA1*gene are responsible for familial cancer and reduced expression of the *BRCA1*gene is frequently observed in sporadic breast \[[@B12],[@B16],[@B20]\] and ovarian tumours \[[@B23]\]. Various mechanisms such as methylation of the CpG islands within the promoter region \[[@B2],[@B6],[@B10],[@B13]\], allelic deletion of the *BRCA1*locus and sequence alterations identified outside the *BRCA1*coding region, especially within the positive regulatory region (PRR) of the *BRCA1*promoter, can modulate the level of BRCA1 expression \[[@B17],[@B19]\]. There are also other mechanisms responsible for breast and ovarian cancer pathogenesis \[[@B5],[@B15]\]. Expression patterns of *BRCA1*mRNAs and differences in their translatability \[[@B14]\] and disruption of the DNA-protein complexes \[[@B18]\] may also contribute to breast/ovarian cancer susceptibility.

Our aim was to investigate the functional effect of sequence alterations within the *BRCA1*promoter/5\'UTR region using luciferase reporter gene assay.

Materials and methods
=====================

Patients
--------

One hundred and fifty patients from families resident in Upper Silesia, Poland, were screened for deletions in the *BRCA1*promoter/5\'UTR region using genomic DNA extracted from peripheral blood lymphocytes using the phenol-chloroform method \[[@B7]\]. Each patient was selected after clinical genetic counselling in which they completed a detailed questionnaire, including family history, after signing an informed consent document. Each person selected for the study was diagnosed with breast and/or ovarian cancer and had a positive family history of breast and/or ovarian cancer.

Screening for new sequence variants within *BRCA1*promoter/5\'UTR
-----------------------------------------------------------------

Eighty-seven patients diagnosed with breast and/or ovarian cancer were selected for *BRCA1*promoter/5\'UTR (GenBank accession no. [U37574](U37574)) screening by direct DNA sequencing. All patients were mutation-negative for founder mutations in the *BRCA1*gene (185delAG, 300T/G, 4153delA, 5382insC) and in the *BRCA2*gene (6174delT, 9631delC) using ASA-PCR and RFLP PCRs analyses \[[@B8],[@B9]\].

PCR amplification was performed using the following primers (forward/reverse, 5\'→3\'): fragment 1 G A C G C T T G G C T C T T T C T G T/TCTGGATCCTCCTCAAGCAC, fragment 2 G A G T G G A T T T C C G A A G C T G A/TCTGGACCTCCTCAAGCAC, fragment 3 G A T G G G A C C T T G T G G A A G A A/CGCGAAGAGCAGATAAATCC. All reactions were performed in 15 *μ*l containing 1 *μ*l 50-150 ng DNA, 1×PCR buffer II (50 mM KCl, 10 mM Tris-HCl pH 8.3), 1.5 mM MgCl, 50 pmol each primer and 1 U of AmpliTaq DNA Polymerase (Applied Biosystem). The PCR cycling conditions were: fragment 1, 94°C for 30 s, 64°C for 30 s, 72°C for 30 s; fragment 2, 94°C for 30 s, 59°C for 30 s, 72°C for 30 s; fragment 3, 94°C for 30 s, 58°C for 30 s, 72°C for 30 s. An initial denaturation for 5 min. at 95°C and a final extension at 72°C for 7 min. were also included in each PCR reaction. All reactions were carried out for 35 cycles on a GeneAmp™ PCR System 2400 (Applied Biosystem) thermal cycler. PCR products were separated in a 2% agarose gel, 1×TBE, stained with ethidium bromide and analysed using Scion Image Beta 4.02 Win Software (Scion Corporation, USA). Amplified products were purified before sequencing with exonuclease I and shrimp alkaline phosphatase according to the manufacturer\'s protocol (Amersham Life Science). Both strands were sequenced using the following primers 5\'→3\': fragment 1 (forward) GACGCTTGGCTCTTTCTGTC, fragment 2 (forward) GTAAGGCGTTGTGAACCCTG and fragment 3 (forward) GGAGACAGGATTTTGTGGGA, fragment 1 (reverse) CAGCCTCCTGAGTAGCTGGA fragment 2 (reverse) TCTGGATCCTCCTCAAGCAC fragment 3 (reverse) CGCGAAGAGCAGATAAATCC. Samples were sequenced with BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystem) and analysed with the ABI Prism 377 DNA automated sequencer (Applied Biosystem).

Allele-specific PCR amplification was used to estimate the frequency of the polymorphic deletion 2223delAAAAA in an additional sixty-three patients of breast/ovarian cancer patients fulfilling the above criteria. The following primers were used: (5\'→3\')TTTAAAAACGTCGGCTGGTC (forward), TCCCACAAAATCCTGTCTCC (reverse) and CAGCCGGTGTGTTTTGTTTT (reverse) with \'touch-down\' PCR: denaturation at 95°C for 5 min. followed by 10 cycles of 94°C 20 s, 65°C 25 s (at this point temperature decreased 0.7°C per cycle), 72°C 30 s and followed by 30 cycles at 94°C 20 s, 58°C 25 s, 72°C 30 s ending with a final extension of 72°C for 7 min. and a quick chill to 4°C. PCR reactions were performed in 15 *μ*l reactions containing 1 *μ*l 50-150 ng DNA, 1×PCR buffer II (50 mM KCl, 10 mM Tris-HCl pH 8.3), 1.5 mM MgCl, 50 pmol each primer and 1 U of AmpliTaq DNA Polymerase (Applied Biosystem). The PCR product was amplified using a Mastercycler ep^®^gradient S (Eppendorf) thermal cycler. The amplified products were separated in 2% agarose gel. The expected size of the PCR fragment containing a polymorphic deletion within exon 1b was 261 bp.

Functional analyses of region BRCA1 promoter/5\'UTR
===================================================

Plasmids
--------

The 1.5 kb DNA region, encompassing minimal *BRCA1*promoter (promoter α), alternative promoter (β), exons 1a, 1b and intron 1, in wild type and in polymorphic forms, was amplified using the primers 5\'→3\': TTTT[GCTAGC]{.ul}CTTTATGGCAAACTCAGGTAG and TTTTA[AGCTT]{.ul}TCTGTTCCAATGAACTTTAAC. The downstream and upstream primers were designed to include *Nhe*I and *Hind*III sites, respectively (underlined). The amplified products were digested with *Nhe*I and *Hind*III and ligated into pGL3-Basic reporter vector (Promega) digested with *Nhe*I and *Hind*III. The pGL3-BRCA1-prom plasmids contain the firefly luciferase gene (*luc*) under the transcriptional and translational control of either the wild type or polymorphic *BRCA1*promoter/5\'UTR region (Figure [2](#F2){ref-type="fig"}). The identity of BRCA1 promoter constructs was confirmed by sequencing. The inserts\' nucleotide sequences were compared with the sequence [U37574](U37574) from GeneBank.

Cell culture, transfection and luciferase assay
-----------------------------------------------

Functional analysis of the *BRCA1*promoter/5\'UTR region was carried out in human non-small cell lung cancer cell line NCI-H1299 and breast cancer cell line MCF7 (obtained from ATCC). Cells were cultured in DMEM or RPMI-1640 medium (respectively) supplemented with 10% foetal calf serum and kept at 37°C and 5% CO~2~. Cell cultures were plated in 12-well culture dishes at 24 hours prior to transfection. At 40% confluence, lung cancer NCI-H1299 and breast cancer MCF7 cells were transfected with 0.5 *μ*g DNA of wild type or polymorphic reporter vectors using FuGene6 (Roche) transfection reagent according to the manufacturer\'s instructions. pRL-TK reporter vector coding for *Renilla*luciferase (Promega) was co-transfected with pGL3-BRCA1-prom plasmids and served as an internal control. The cells were incubated with FuGene6-DNA for 24 hours. Subsequently the cells were washed in phosphatate buffered saline, lysed in 250 *μ*l 1× Passive Lysis Buffer and 20 *μ*l of the cell lysates were assayed using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was divided by *Renilla*luciferase activity, which yielded normalized firefly luciferase activity. This normalization helps to minimize the confounding influence of differences in cell number, transfection efficiency, etc. Each pGL3-BRCA1-prom plasmid version was transfected to the three wells of the 12-well plate. The mean and standard deviation from three luciferase measurements were calculated and the statistical significance of the differences were estimated using the *t*-test.

Results and discussion
======================

One hundred and fifty patients with breast and/or ovarian cancer from Upper Silesia in Poland were screened for sequence alterations in the 5\' region of *BRCA1*.

The polymorphic deletion 2223delAAAAA (according to the GeneBank Acc. [U37574](U37574)) within *BRCA1*exon 1b was detected in three families (2%). Two linked nucleotide sequence alterations within the *BRCA1*intron 1 2642A\>T, 2743T\>C (Acc. [U37574](U37574)) were also detected in 16 patients (18.4%) (Figure [1](#F1){ref-type="fig"}).

The functional impact of the most frequent sequence variants within the 5\' region of *BRCA1*was analysed by the Dual-Luciferase Reporter Assay System (Promega) in the lung cancer cell line (NCI-H1299) and breast cancer cell line (MCF-7). Normalized firefly luciferase activity was significantly lower in the MCF7 cell line compared with the NCI-H1299 cell line (Figure [3](#F3){ref-type="fig"}).

All tested variants of the *BRCA1*promoter/5\'UTR induced expression of the reporter gene at levels very similar to the wild-type sequence in NCI-H1299 cell line (2.15 ± 0.32 and 2.02 ± 0.27 versus 1.84 ± 0.123; P = 0.19, *t*-test; Figure [3](#F3){ref-type="fig"}). The polymorphic sequences slightly reduced expression of reporter *luc*gene compared with wild-type *BRCA1*promoter/5\'UTR in MCF7 cell line (0.51 ± 0.024 and 0.55 ± 0.012 versus 0.6 ± 0.07); however, the differences were not significant (P = 0.089, P = 0.263, *t*-test, respectively; Figure [3](#F3){ref-type="fig"}). The evidence from this study suggests that the first polymorphism under investigation could only slightly modulate the levels of expression of the *BRCA1*gene while the second polymorphism (deletion of 5 nucleotides) did not demonstrate any change in functional activity in the experimental system used in this study.

The 5\' region of *BRCA1*contains multiple functional domains which may regulate translation, transcription and alternative splicing of *BRCA1*\[[@B21],[@B22]\]. In this study we analysed the *BRCA1*5\' region and detected several sequence alterations. We cloned the region of interest of the *BRCA1*gene into the reporter plasmid in order to find out if the sequence alterations modulate the expression of the reporter gene. The deletion of five adenines is a major sequence change. It is located in exon 1b, which is an alternative exon present in the mRNA mostly in cancer cells \[[@B21],[@B14]\]. It may change the secondary structure of the 5\'UTR of the alternative mRNA, influencing translation efficiency. However, we did not detect its influence on the reporter gene in either of the two cancer cell lines that we used for the assay. The two linked substitutions are located at the 3\' end of intron 1. In principle, they may modulate the efficiency or accuracy of RNA splicing. However, in the case of these linked sequence changes, we observed no influence on reporter gene expression. Therefore, we conclude that the sequence alterations have no major functional impact on *BRCA1*expression. However, we cannot rule out the possibility that they change regulation of *BRCA1*expression in normal cells or when present in their proper chromatin environment. Interestingly, we noticed that the activity of the reporter gene controlled by *BRCA1*promoter is significantly lower in the MCF7 breast cancer cell line compared with the lung cancer cell line (Fig. [3](#F3){ref-type="fig"}). Normalized firefly luciferase activity can be regarded as a ratio of experimental promoter activity (*BRCA1*in this case) to the control promoter activity (thymidine kinase gene promoter from herpes simplex virus). This ratio is significantly lower in MCF7 cells. This is consistent with the observation of decreased *BRCA1*protein level in breast cancer cell lines and primary breast carcinomas associated with the increased expression of negative regulators of *BRCA1*promoter \[[@B1]\]. Methylation of the *BRCA1*promoter region also decreases the expression level of the protein \[[@B3]\], but this mechanisms is found in a small number of *BRCA1*negative breast cancer specimens \[[@B1]\].

NFLA - normalized firefly luciferase activity

SUB - *BRCA1*fragment with two linked nucleotide substitutions: 2642A\>T, 2743T\>C

DEL - *BRCA1*fragment with deletion: 2223delAAAAA

![**Schematic representation of the 5\' region of the *BRCA1*gene and location of sequence alterations found in this gene fragment -1a and 1b represent two alternative first exons, 2 represents the exon 2 with the translation start site**.](1897-4287-4-1-20-1){#F1}

![**The pGL3 - *BRCA1*- prom plasmid map**. The localization of sequence alterations and the recognition sequences of the restriction enzymes used for the cloning are shown. The thick arrow represents the coding region of the firefly luciferase gene (*luc*)](1897-4287-4-1-20-2){#F2}

![The normalized activity of the reporter gene (*luc*) under transcriptional and translational control of the wild-type and polymorphic forms *BRCA1*promoter/5\'UTR region in NCI-H1299 (grey) and MCF7 (dark grey) cell lines](1897-4287-4-1-20-3){#F3}
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